Transaction details
Voyager Therapeutics NASDAQ:VYGR President and Chief Executive Officer Alfred Sandrock sold 14,197 shares of the companys common stock on February 24, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The sale was executed at prices ranging from $3.61 to $3.86 per share, producing gross proceeds of $53,806.
Ownership after the sale
Following the disposition, Sandrock directly owns 484,060 shares of Voyager Therapeutics common stock. The filing indicates the sale was not a discretionary market trade but was implemented under an automatic sale instruction that Sandrock adopted on May 12, 2025.
Reason for the sale
The Form 4 states the transaction was made to cover tax withholding obligations associated with restricted stock units that vested on February 21, 2026. The sale therefore served a specific tax-related purpose rather than signaling a broader, discretionary liquidation of holdings.
Market context and valuation note
At the time of reporting the stock had rallied nearly 20 percent over the previous week and was trading at $4.18. The filing includes an InvestingPro analysis noting that Voyager Therapeutics appears undervalued at current market levels and that the company holds more cash than debt on its balance sheet.
What this means
- The transaction was carried out under a pre-arranged plan put in place in May 2025 and was tied to RSU vesting on February 21, 2026.
- Sandrocks direct ownership remained substantial after the sale, at 484,060 shares.
- Independent analysis cited in the filing describes the stock as appearing undervalued and highlights a cash-heavy balance sheet relative to debt.
The filing supplies a factual record of an insider sale that was executed for tax compliance related to equity compensation. The documentation does not provide commentary on future management intentions or corporate strategy beyond the stated purpose of the sale.